Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer

Abstract

(1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to distant visceral organs with or without para-aortic lymph node metastasis (IVB) to identify primary tumor size and concurrent chemoradiotherapy. (3) Results: The overall survival (OS) for patients with a tumor >6.9 cm in size was significantly poorer than that for patients with a tumor ≤6.9 cm in the IVB group (p = 0.0028); the corresponding five-year OS rates in patients with a tumor ≤6.9 and >6.9 cm were 53.3% and 13.4%, respectively. In the multivariate analysis, tumor size and primary treatment were significantly associated with survival in metastatic cervical cancer. (4) Conclusions: Tumor size ≤6.9 cm and concurrent chemoradiotherapy as the primary treatment were favorable prognostic factors for patients with metastatic cervical cancer.

Keywords: biomarker; concurrent chemoradiotherapy; metastatic cervical cancer; prognosis; tumor size.

Figure 1

Receiver operating characteristic curve analysis of tumor diameter in the greatest dimension. The area under the curve for tumor diameter in the greatest dimension was 0.779.

Figure 2

Kaplan–Meier curve showing overall survival (OS) stratified by tumor size in the IVB group. Curves show OS stratified by tumor size at the cut-off of 6.9 cm. p-value was calculated with the log-rank test.